+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells

Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells

Journal of Clinical Oncology 24(18_Suppl): 637-637

NlmCategory="UNASSIGNED">637 Background: Breast cancer growth is tightly regulated by interactions between growth factor and estrogen receptors. Dimerization is crucial for activation of HER receptors (EGFR, HER2, HER3, HER4) that contribute to modulation of tumor progression and the failure of antiestrogen therapy. HER2 is the preferred dimerization partner in a process stimulated by the several HER receptor ligands. HER2 antibody (trastuzumab) shows antitumor efficacy in HER2-overexpressing cancers. New antibodies that disrupt HER2 dimerization (pertuzumab) may be useful in treating cancers with normal HER2 levels. Estrogen receptor (ER)-positive tumor cells with normal HER levels (MCF-7, ZR75), as well as cells engineered for HER2-overexpression (MCF-7/HER2, ZR75/HER2) or tamoxifen resistance (MCF-7/TAM), were grown in vitro and as xenografts in nude mice and treated with tamoxifen, fulvestrant (Faslodex), trastuzumab or pertuzumab, alone or combined. Effects of agents on phosphorylation of ER and coactivator AIB1, ER-dependent transcripts, p27 and VEGF secretion were assessed. Growth of ER-positive tumors with low HER is reduced by tamoxifen and fulvestrant. In contrast, HER2-overexpressing tumors are tamoxifen-resistant but retain sensitivity to fulvestrant and show greater, synergistic antitumor effects with trastuzumab-fulvestrant combined. Similarly, non-HER2-overexpressing tumors with or without tamoxifen resistance are sensitive to fulvestrant, but fulvestrant-pertuzumab elicits more profound antitumor effects (P<0.001). Enhanced inhibitory action of fulvestrant-pertuzumab is related, in part, to changes in phosphorylation of ER and AIB1, leading to blockade of ER-induced transcripts, as well as nuclear localization of p27, a CDK-inhibitor that downregulates cell proliferation. Further, enhanced tumor secretion of VEGF after estrogen and HER signaling is markedly reduced by fulvestrant-pertuzumab as compared with either agent alone (P<0.001). Pertuzumab promotes antitumor efficacy of the pure antiestrogen, fulvestrant, and dual disruption of ER and HER signaling may be a new way to optimize hormonal therapy and overcome antiestrogen resistance. Supported by US Army BCRP and Stiles Program. [Table: see text].

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 058071546

Download citation: RISBibTeXText

PMID: 27952087

Related references

Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Research & Treatment 82(Suppl. 1): S12-S13, 2003

Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. Febs Letters 587(20): 3327-3334, 2013

Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative. Molecular and Cellular Endocrinology 338(1-2): 68-78, 2011

Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. Journal of Biological Chemistry 276(26): 23763-8, 2001

Targeting notch signaling and estrogen receptor pathways in human breast cancer stem cells. Journal of Clinical Oncology 26(15_Suppl): 22066-22066, 2016

Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Molecular Endocrinology 22(8): 1781-1796, 2008

Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. Journal of Clinical Oncology 32(10): 1084-1086, 2014

Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148(8): 4091-4101, 2007

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. Nuclear Medicine and Molecular Imaging 50(3): 246-254, 2016

Isolation of a heregulin-like growth factor secreted by estrogen receptor-negative MDA-MB-231 human breast cancer cells that stimulates estrogen receptor-positive cells. Biochemical and Biophysical Research Communications 202(3): 1357-1365, 1994

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clinical Cancer Research 24(12): 2804-2811, 2018

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 enhances the antitumor effect of the antiestrogen ICI 182,780 in estrogen-receptor-positive breast cancer cells. Breast Cancer Research & Treatment 76(Suppl. 1): S71, 2002

Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Gynecologic Oncology 94(3): 705-712, 2004

Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Molecular Endocrinology 19(11): 2660-2670, 2005

Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Research 61(18): 6747-6754, 2001